Wall Street sentiment is gloomy this morning after closing lower in yesterday’s session. All major indices remain close to record highs, but are tracking losses in early trading.
Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.
This golden age is also presenting tremendous opportunities for investors. Biotech stocks offer the potential for huge long-term returns. Today’s trade alert highlights a biotech stock that boasts a strong pipeline and already has a few winning drugs on the market and there appears to be plenty of room for upside expansion in 2021.
New in Biotech:
The Guardian: “New pill could spell the end of all disease.”
This pill is set to completely change the lives of millions of Americans.
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams. [Full Story…]
GlaxoSmithKline (GSK), well-known for its vaccines as well as respiratory drug Advair, is a transformation story that’s been underway since CEO Emma Walmsley took over in April 2017.
Walmsley’s plan includes spinning out consumer products like Sensodyne toothpaste, Advil pain reliever and Centrum vitamins in a joint deal with Pfizer, although that has been delayed. GSK is also divesting other assets, such as a joint spin-off with Pfizer, although that has been delayed. The company also continues to divest other assets, such as plants in Poland and Canada.
The company’s top immunology drug, Nucala, is used in some cases of asthma and was recently approved for treating a rare blood disorder called hypereosinophilic syndrome, or HES. The drug works by preventing a protein from binding to white blood cells.
Argus Research’s Eade “Buy” calls GSK‘s price a buying opportunity and has a 12-month price target of $50 on the stock. He also calls out an attractive 5.23% dividend yield and says GSK shares trade below industry averages.
UBS’s Sutcliffe also sees GSK as a Buy. “The HIV business experienced a recent flattening of US sales, but new products mean the franchise has now returned to modest growth,” she writes. “Launch of a new injectable should further boost growth and we see mid-single-digit HIV sales CAGR through 2023.”
With a trailing twelve month price to earnings ratio of 12.93, GSK seems to have plenty of runway ahead in the mid term. Of 7 analysts offering recommendations for the stock, 3 rate it a Buy and 4 rate GSK a Hold. There are no Sell ratings for the stock.
Where to invest $1,000 right now...
Before you consider buying GlaxoSmithKline, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not GlaxoSmithKline.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
New Banking Rule Set to Affect 234 Million Americans
Most people will be caught by surprise, but the few who prepare now could come out of this wealthier than they ever thought possible…[Full Story…]